User profiles for D. C. Wheeler

David Wheeler

virginia commonweath university
Verified email at vcu.edu
Cited by 6124

[HTML][HTML] Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

…, A Levin, C Pollock, DC Wheeler… - New England journal …, 2019 - Mass Medical Soc
Background Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few
effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–…

Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy

…, C Pollock, P Stenvinkel, KR Tuttle, DC Wheeler… - The Lancet, 2017 - thelancet.com
The global nephrology community recognises the need for a cohesive plan to address the
problem of chronic kidney disease (CKD). In July, 2016, the International Society of …

[HTML][HTML] Chronic kidney disease as a global public health problem: approaches and initiatives–a position statement from Kidney Disease Improving Global Outcomes

…, M Jadoul, A Levin, NR Powe, J Rossert, DC Wheeler… - Kidney international, 2007 - Elsevier
Chronic kidney disease (CKD) is increasingly recognized as a global public health problem.
There is now convincing evidence that CKD can be detected using simple laboratory tests, …

[HTML][HTML] Dapagliflozin in patients with chronic kidney disease

…, RD Toto, AM Langkilde, DC Wheeler - … England Journal of …, 2020 - Mass Medical Soc
Background Patients with chronic kidney disease have a high risk of adverse kidney and
cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, …

[HTML][HTML] Intravenous iron in patients undergoing maintenance hemodialysis

…, H Murray, CRV Tomson, DC Wheeler… - … England Journal of …, 2019 - Mass Medical Soc
Background Intravenous iron is a standard treatment for patients undergoing hemodialysis,
but comparative data regarding clinically effective regimens are limited. Methods In a …

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes …

…, M Sousa-Uva, P Valensi, DC Wheeler - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

…, KW Mahaffey, DM Charytan, DC Wheeler… - The lancet Diabetes & …, 2019 - thelancet.com
Background The effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on kidney
failure, particularly the need for dialysis or transplantation or death due to kidney disease, is …

New-onset diabetes after transplantation: 2003 international consensus GUIDELINES1

…, M Markell, FJ Van Der Woude, DC Wheeler - …, 2003 - journals.lww.com
Diabetes mellitus is 1one of the most common chronic diseases in the world, with an estimated
worldwide prevalence of over 176 million in 2000. Furthermore, the prevalence of the …

[HTML][HTML] EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: Evidence for a PPAR-γ–dependent mechanism

…, SH Powis, R Fernando, WY Mon, DC Wheeler… - Kidney international, 2005 - Elsevier
EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: Evidence for a
PPAR-γ–dependent mechanism. Background Recent studies have shown that fish oil, …

[HTML][HTML] The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a …

…, MJ Landray, C Reith, J Emberson, DC Wheeler… - The Lancet, 2011 - thelancet.com
Background Lowering LDL cholesterol with statin regimens reduces the risk of myocardial
infarction, ischaemic stroke, and the need for coronary revascularisation in people without …